Reyon Pharmaceutical Co Ltd (102460) — Cash Flow-to-Debt Ratio
Reyon Pharmaceutical Co Ltd (102460) has a Cash Flow-to-Debt Ratio of -0.01x as of September 2025, meaning its operating cash flow of ₩-1.73 Billion could theoretically repay 0% of its total liabilities (₩239.99 Billion) in one year. Explore Reyon Pharmaceutical Co Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Reyon Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2008–2024)
Historical debt coverage capacity for Reyon Pharmaceutical Co Ltd across 13 annual periods. Also explore how large is Reyon Pharmaceutical Co Ltd's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Reyon Pharmaceutical Co Ltd (2008–2024)
Year-by-year debt coverage analysis for Reyon Pharmaceutical Co Ltd. For market capitalisation and broader financial context, see how much is Reyon Pharmaceutical Co Ltd worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.01x | ₩-1.44 Billion | ₩250.05 Billion | ▼ -116.7% |
| 2023 | 0.03x | ₩8.65 Billion | ₩251.15 Billion | ▼ -6.6% |
| 2022 | 0.04x | ₩8.73 Billion | ₩236.93 Billion | ▼ -26.6% |
| 2021 | 0.05x | ₩11.68 Billion | ₩232.74 Billion | ▼ -4.5% |
| 2020 | 0.05x | ₩4.60 Billion | ₩87.52 Billion | ▲ +122.5% |
| 2019 | -0.23x | ₩-12.18 Billion | ₩52.19 Billion | ▼ -258.6% |
| 2018 | 0.15x | ₩11.45 Billion | ₩77.77 Billion | ▼ -37.5% |
| 2017 | 0.24x | ₩16.76 Billion | ₩71.18 Billion | ▼ -24.3% |
| 2016 | 0.31x | ₩9.47 Billion | ₩30.44 Billion | ▼ -61.4% |
| 2012 | 0.81x | ₩24.65 Billion | ₩30.57 Billion | ▲ +51.0% |
| 2011 | 0.53x | ₩15.34 Billion | ₩28.73 Billion | ▲ +36.2% |
| 2009 | 0.39x | ₩8.68 Billion | ₩22.15 Billion | ▲ +48.2% |
| 2008 | 0.26x | ₩5.99 Billion | ₩22.64 Billion | — |